PremiumRatingsRepligen’s Strategic Acquisition of 908 Devices’ Bioprocessing Assets Boosts Buy Rating Repligen acquires bioprocessing analytic portfolio from 908 Devices for $70M Repligen purchases 908 Devices’ bioprocessng analytics portfolio for $70M PremiumThe FlyRepligen price target raised to $170 from $165 at Canaccord Repligen Corporation Announces 2024 Financial Results Hold Rating for Repligen Amid Mixed Performance and Modest Growth Projections PremiumPre-EarningsIs RGEN a Buy, Before Earnings? Amazon downgraded, Shopify upgraded: Wall Street’s top analyst calls “Top-Tier”Repligen to Outperform Peers Thanks to AI and Low China Exposure 
